For many decades, cancer treatment has relied on surgery, chemotherapy, and radiation therapy. Over the past decade, immunotherapy, therapies that stimulate and strengthen the power of a patient's immune system to attack tumors, has rapidly become an important cog in the wheel of cancer treatment. One form of immunotherapy, called CAR T-cell therapy, has generated tremendous excitement among researchers and oncologists alike.
Chimeric antigen receptor (CAR)-T ceolls are genetically modified T cells that are collected from a patient's blood and modified in the lab to express a tumor antigen-specific cell- which has the specificity of antigen-binding domain from a B cell receptor making it specific for a type of the target cell, and it is fused to the intracellular domain of a CD3 T cell giving it the cytotoxic power to kill the specific cancer cell, hence the name Chimeric antigen receptor (CAR)-T cell.
EXPANDING THE REACH
Efforts are underway to address challenges related to manufacturing and scalability. Streamlining the production process and increasing the accessibility of CAR T-cell therapy could make it more readily available to patients around the world. India has a handful of companies which have either already received DCGI approval, or are in the process of receiving the same.
The Food and Drug Administration (FDA) has approved six CAR-T cell therapies for hematological cancers (blood cancers) since 2017. Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) were the first two CAR-T products to receive approval. They are used for treating patients up to 25 years old with refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL), and adults with refractory or relapsed diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapies.
Esta historia es de la edición June 2024 de Healthcare Radius.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición June 2024 de Healthcare Radius.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Dengue-related searches surge on Justdial
Justdial data reveals significant increase in dengue-related searches and pest control services this monsoon season, amid severe dengue outbreak in India.
Ipca launches NovaLead's Diulcus for diabetic foot ulcer
Ipca Laboratories launches NovaLead's patented drug Diulcus, for the treatment of diabetic foot ulcer in India.
Sahyadri Hospitals unveils advanced radiotherapy treatment
Sahyadri Hospitals launches Asia's first advanced radiotherapy treatment, Radixact X9 system with Vital Hold technology for precise cancer treatment.
Complex liver transplant saves diabetic patient
Wockhardt Hospitals, Mumbai Central and South Asian Liver Institute provide liver transplant services to a Botswanian patient.
Gynecological cancers rise in young Indian women
Experts stress need for awareness, early screening, and advanced treatment options like robotic-assisted surgery for gynecological cancers.
Mahajan Imaging, Siemens unveil AI diagnostic analyzer
Mahajan Imaging and Labs and Siemens Healthineers launch India's first Al-diagnostic analyzer.
Nimotuzumab boosts head and neck cancer survival - Tata Memorial study
A Tata Memorial study finds Nimotuzumab increases 10-year survival rate for head and neck cancer patients.
Kolkata doctor rape and murder: Everything you wanted to know
Protesting doctors demand better workplace safety and stricter policy measures.
AYUSH treatments to be covered under PM-JAY?
Very soon, AYUSH treatments may be covered under AB PM-JAY.
WHAT DOCTORS MUST TELL PATIENTS ABOUT DRY EYE SYNDROME
Dry eye syndrome affects lakhs of people globally, causing discomfort and vision issues. Learn how doctors must guide patients about managing it.